Pharmacoeconomics of adverse drug reactions

Fundamental and Clinical Pharmacology

Volumn 18, Issue 3, 2004, Pages 275-280

  Lundkvist, Jonas ^a   Jönsson, Bengt ^a  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Adverse effects; Cost; Side effects

Indexed keywords

TUBERCULOSTATIC AGENT; VACCINE;

COST BENEFIT ANALYSIS; DECISION MAKING; DRUG HYPERSENSITIVITY; ECONOMIC ASPECT; HOSPITALIZATION; HUMAN; INCIDENCE; PRIORITY JOURNAL; REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; SAFETY MANAGEMENT;

EID: 2942511325     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2004.00239.x     Document Type: Review

References (16)

1. Einarson T.R. Drug-related hospital admissions. Ann. Pharmacother. (1993) 27 832-840.
2. Dartnell J.G., Anderson R.P., Chohan V. et al. Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med. J. Aust. (1996) 164 659-662.
3. Easton K.L., Parsons B.J., Starr M., Brien J.E. The incidence of drug-related problems as a cause of hospital admissions in children. Med. J. Aust. (1998) 169 356-359.
4. Pouyanne P., Haramburu F., Imbs J.L., Begaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ (2000) 320 1036.
5. Cooper J. Adverse drug reaction-related hospitalization of nursing facility patients: A 4-year study. Southern Med. J. (1999) 92 285-290.
6. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta- analysis of prospective studies. JAMA (1998) 279 1200-1205.
7. Lapeyere-Mestre M., Gary J., Machelard-Roumagnac M., Bonhomme C., Nugat R., Montastruc J. Incidence and cost of adverse drug reactions in a French cancer institute. Eur. J. Clin. Pharmacol. (1997) 53 19-22.
8. Lagnaoui R., Moore N., Fach J., Longy-Boursier M., Begaud B. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur. J. Clin. Pharmacol. (2000) 56 181-186.
9. Moore N., Lecointre D., Noblet C., Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br. J. Clin. Pharmacol. (1998) 45 301-308.
10. Bates D., Spell N., Cullen D. et al. The costs of adverse drug events in hospitalized patients. Adverse drug events prevention study group. JAMA (1997) 277 307-311.
11. Classen D.C., Pestotnik S.L., Evans R.S., Lloyd J.F., Burke J.P. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA (1997) 277 301-306.
12. Dormann H., Muth-Selbach U., Krebs S. et al. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf. (2000) 22 161-168.
13. Schneider P.J., Gift M.G., Lee Y.P., Rothermich E.A., Sill B.E. Cost of medication-related problems at a university hospital. Am. J. Health Syst. Pharm. (1995) 52 2415-2418.
14. Johnson J.A., Bootman J.L. Drug-related morbidity and mortality. A cost-of-illness model. Arch. Intern. Med. (1995) 155 1949-1956.
15. Bootman J., Harrison D., Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch. Intern. Med. (1997) 157 2089-2096.
16. Johnson J.A., Bootman J.L. Drug-related morbidity and mortality and the economic impact of pharmaceutical care. Am. J. Health Syst. Pharm. (1997) 54 554-558.